Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.37 |
| ▸ | ITGAV | P06756 | 5/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.37 |
| ▸ | NQO2 | P16083 | 3/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA9 | Q16790 | 3/20 | 0.32 |
| ▸ | XIAP | P98170 | 2/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7071334 | 0.98 | ITGB3 (0.37) | ITGB3ITGAVITGA2BNQO2MTNR1A | |
| SCHEMBL7071310 | 0.96 | ITGB3 (0.36) | ITGB3ITGAVITGA2BNQO2MTNR1A | |
| Trifluoroacetic Acid SCHEMBL7078830 | 0.89 | ITGB3 (0.44) | ITGB3ITGAVITGA2BXIAPF10 | |
| Trifluoroacetic Acid SCHEMBL7071328 | 0.87 | ITGB3 (0.45) | ITGB3ITGAVITGA2BF10 | |
| Trifluoroacetic Acid SCHEMBL7071305 | 0.85 | ITGB3 (0.43) | ITGB3ITGAVITGA2BNQO2MTNR1A | |
| SCHEMBL7078547 | 0.81 | DRD2 (0.35) | ITGB3ITGAVITGA2BMTNR1AMTNR1B | |
| SCHEMBL7078812 | 0.80 | ITGB3 (0.34) | ITGB3ITGAVITGA2BMTNR1AMTNR1B | |
| SCHEMBL7076563 | 0.79 | XIAP (0.46) | ITGB3ITGAVITGA2BXIAP | |
| SCHEMBL7073213 | 0.78 | XIAP (0.45) | ITGB3ITGAVITGA2BXIAP | |
| SCHEMBL7075830 | 0.77 | XIAP (0.46) | ITGB3ITGAVITGA2BXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | WYETH (US) | 2003-06-12 | — | — | US | disclosed |
| US-6429214-B1 | INHIBITORS OF BONE RESORPTION | WYETH | 2002-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | ITGAV, ITGB2, ITGB3 | ITGB3 3/4885ITGAV 1/4885ITGA2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.